Health officials say it's important to get flu and COVID-19 vaccines ahead of the holidays when respiratory bugs tend to spread ...

Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to ...

MODERNA reported a surprise third-quarter profit on Thursday (Nov 7), driven by cost cutting and higher-than-expected sales ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

One stock yields 6% today. Another has grown its dividend by 460% over the past decade. Both are blue chip bargains to buy ...

Johnson & Johnson announced at its booth the China market launch of INVEGA HAFYERA, a medicine for the treatment of ...

The Molecular Glue Drug Development Summit returns to Boston with fresh insights and opportunities! With powerhouse partnerships lighting up the industry—like Biogen & Neomorph, Inc.’s groundbreaking ...

Pfizer's diverse operations put it in an excellent position to grow in the long run. It doesn't have a top weight loss treatment on the market, but that could change. Its above-average dividend yield ...

They found that mRNA vaccines that target C. diff cells and the toxins they produce generated a lasting immune response in mice and hamsters.

An influx of late-phase programs has prompted Genmab to reassess its bets. | An influx of late-phase programs has prompted Genmab to reassess its bets. The biotech is axing three early-stage clinical ...